New York State Department Of Health Provides Clinical Laboratory Evaluation Program Test Approval To Niki BioSolutions' DiamiR Biosciences Subsidiary For Its APOE Genotyping Test

Benzinga · 3d ago

Niki BioSolutions, Inc. (NASDAQ: NIKI) ("Niki BioSolutions" or the "Company"), a clinical-stage life sciences company focused on developing advanced genomic and biomarker testing solutions, today announced that its wholly-owned subsidiary, DiamiR Biosciences Corp. ("DiamiR"), has received a Clinical Laboratory Evaluation Program (CLEP) Test Approval from the New York State Department of Health (NYSDOH) expanding the approved specimen types for its APOE Genotyping test which identifies genetic variants associated with the risk for Alzheimer’s disease and other conditions.